Research reportd-cycloserine injected into the dorsolateral periaqueductal gray induces anxiolytic-like effects in rats

- D-cycloserine (DCS) is a partial agonistpe of the NMDA receptor-associated glycine site.
- DCS, in lower doses, acts as agonist, but in higher acts as antagonist.
- Anxiolytic-like effect has been observed only after systemic administration of high doses of DCS.
- Glycine site associated with the NMDAR in the dlPAG modulates defensive behavior.
- Intra-dlPAG DCS administration induced anxiolytic-like effects in three different animal models.

d-cycloserine (DCS) is a partial agonist of the glycine site coupled to the NMDA receptor (NMDAR). As a consequence, depending on the doses used it can function as an agonist or antagonist at this site. In rodents, anxiolytic-like effects have been observed after the systemic administration of high doses of DCS. The brain sites of these effects have not been investigated. Direct brain injection of glycine site antagonists or agonists into the dorsolateral periaqueductal gray (dlPAG), a brain structure involved in the modulation of defensive-related behaviors, produces anxiolytic- or anxiogenic-like effects, respectively. The present study investigated if the dlPAG could be a brain site of the anxiolytic effects observed after DCS systemic administration. Male Wistar rats received intra-dlPAG injections of DCS (25, 50, 100 or 200 nmol) and were exposed to the elevated plus-maze (EPM) or to the light-dark box. DCS, at the dose of 200 nmol, increased open arm exploration and the time spent in the light compartment, respectively. Based on this result we tested the effects of intra-dlPAG DCS (200 nmol) administration in animals submitted to the Vogel conflict tests. Anxiolytic-like effect was also observed in this test indicated by the increase of punished responses. The drug did not change locomotor activity, discarding potential confounding factors. These results indicated that administration of DCS, a partial agonist of the NMDAR-associated glycine site, into the dlPAG induces anxiolytic-like effects in different models, pointing to a possible site of action of this compound.